J. Jonkers, et.al., Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer., Nature genetics, 2001, 29

http://rdf.ncbi.nlm.nih.gov/pubmed/11694875

J. Jonkers, et.al., Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer., Nature genetics, 2001, 29

pubmed

allele

http://purl.org/net/cito/citesAsAuthority

• Brca2<tm1.1Brn>
  http://metadb.riken.jp/db/mgi_rdf/MGI:2156644
• Trp53<tm1.1Brn>
  http://metadb.riken.jp/db/mgi_rdf/MGI:2156651
• Brca2<tm1Brn>
  http://metadb.riken.jp/db/mgi_rdf/MGI:2156556
• Tg(KRT14-cre)8Brn
  http://metadb.riken.jp/db/mgi_rdf/MGI:2177243

class

http://purl.org/net/cito/citesAsAuthority

• Brca2<tm1.1Brn>
  http://metadb.riken.jp/db/mgi_rdf/MGI:2156644
• Trp53<tm1.1Brn>
  http://metadb.riken.jp/db/mgi_rdf/MGI:2156651
• Brca2<tm1Brn>
  http://metadb.riken.jp/db/mgi_rdf/MGI:2156556
• Tg(KRT14-cre)8Brn
  http://metadb.riken.jp/db/mgi_rdf/MGI:2177243

表現型アノテーション

http://purl.org/net/cito/citesAsAuthority

• decreased tumor latency_Trp53<tm1.1Brn>/Trp53<tm1.1Brn>
  http://metadb.riken.jp/0010308I129P2OlaHsdBALBcJFVBNTrp53tm11BrnTrp53tm11BrnTrp53tm11Brn
• increased skin tumor incidence_Brca2<tm1Brn>/Brca2<tm1Brn>,Trp53<tm1Brn>/Trp53<tm1Brn>,Tg(KRT14-cre)8Brn/0
  http://metadb.riken.jp/0010300I129P2OlaHsdFVBNBrca2tm1BrnBrca2tm1BrnTrp53tm1BrnTrp53tm1BrnTgKRT14cre8Brn0Trp53tm1BrnTgKRT14cre8BrnBrca2tm1Brn
• increased mammary adenocarcinoma incidence_Brca2<tm1Brn>/Brca2<tm1Brn>,Trp53<tm1Brn>/Trp53<tm1Brn>,Tg(KRT14-cre)8Brn/0
  http://metadb.riken.jp/0001883I129P2OlaHsdFVBNBrca2tm1BrnBrca2tm1BrnTrp53tm1BrnTrp53tm1BrnTgKRT14cre8Brn0Trp53tm1BrnTgKRT14cre8BrnBrca2tm1Brn
• increased tumor incidence_Brca2<tm1Brn>/Brca2<+>,Trp53<tm1Brn>/Trp53<tm1Brn>,Tg(KRT14-cre)8Brn/0
  http://metadb.riken.jp/0002020I129P2OlaHsdFVBNBrca2tm1BrnBrca2Trp53tm1BrnTrp53tm1BrnTgKRT14cre8Brn0Brca2tm1BrnTgKRT14cre8BrnTrp53tm1BrnBrca2
• increased mammary gland tumor incidence_Brca2<tm1Brn>/Brca2<tm1Brn>,Trp53<tm1Brn>/Trp53<+>,Tg(KRT14-cre)8Brn/0
  http://metadb.riken.jp/0010299I129P2OlaHsdFVBNBrca2tm1BrnBrca2tm1BrnTrp53tm1BrnTrp53TgKRT14cre8Brn0Trp53tm1BrnTrp53TgKRT14cre8BrnBrca2tm1Brn
• increased tumor incidence_Brca2<tm1Brn>/Brca2<tm1Brn>,Trp53<tm1Brn>/Trp53<+>,Tg(KRT14-cre)8Brn/0
  http://metadb.riken.jp/0002020I129P2OlaHsdFVBNBrca2tm1BrnBrca2tm1BrnTrp53tm1BrnTrp53TgKRT14cre8Brn0Trp53tm1BrnTrp53TgKRT14cre8BrnBrca2tm1Brn
• increased tumor incidence_Trp53<tm1.1Brn>/Trp53<tm1.1Brn>
  http://metadb.riken.jp/0002020I129P2OlaHsdBALBcJFVBNTrp53tm11BrnTrp53tm11BrnTrp53tm11Brn
• no abnormal phenotype detected_Trp53<tm1Brn>/Trp53<tm1Brn>
  http://metadb.riken.jp/0002169I129P2OlaHsdFVBNTrp53tm1BrnTrp53tm1BrnTrp53tm1Brn
• increased skin tumor incidence_Brca2<tm1Brn>/Brca2<+>,Trp53<tm1Brn>/Trp53<tm1Brn>,Tg(KRT14-cre)8Brn/0
  http://metadb.riken.jp/0010300I129P2OlaHsdFVBNBrca2tm1BrnBrca2Trp53tm1BrnTrp53tm1BrnTgKRT14cre8Brn0Brca2tm1BrnTgKRT14cre8BrnTrp53tm1BrnBrca2
• increased mammary adenocarcinoma incidence_Brca2<tm1Brn>/Brca2<+>,Trp53<tm1Brn>/Trp53<tm1Brn>,Tg(KRT14-cre)8Brn/0
  http://metadb.riken.jp/0001883I129P2OlaHsdFVBNBrca2tm1BrnBrca2Trp53tm1BrnTrp53tm1BrnTgKRT14cre8Brn0Brca2tm1BrnTgKRT14cre8BrnTrp53tm1BrnBrca2
• increased mammary gland tumor incidence_Brca2<tm1Brn>/Brca2<+>,Trp53<tm1Brn>/Trp53<tm1Brn>,Tg(KRT14-cre)8Brn/0
  http://metadb.riken.jp/0010299I129P2OlaHsdFVBNBrca2tm1BrnBrca2Trp53tm1BrnTrp53tm1BrnTgKRT14cre8Brn0Brca2tm1BrnTgKRT14cre8BrnTrp53tm1BrnBrca2
• increased mammary gland tumor incidence_Brca2<tm1Brn>/Brca2<tm1Brn>,Trp53<tm1Brn>/Trp53<tm1Brn>,Tg(KRT14-cre)8Brn/0
  http://metadb.riken.jp/0010299I129P2OlaHsdFVBNBrca2tm1BrnBrca2tm1BrnTrp53tm1BrnTrp53tm1BrnTgKRT14cre8Brn0Trp53tm1BrnTgKRT14cre8BrnBrca2tm1Brn
• increased tumor incidence_Brca2<tm1Brn>/Brca2<tm1Brn>,Trp53<tm1Brn>/Trp53<tm1Brn>,Tg(KRT14-cre)8Brn/0
  http://metadb.riken.jp/0002020I129P2OlaHsdFVBNBrca2tm1BrnBrca2tm1BrnTrp53tm1BrnTrp53tm1BrnTgKRT14cre8Brn0Trp53tm1BrnTgKRT14cre8BrnBrca2tm1Brn
• increased skin tumor incidence_Brca2<tm1Brn>/Brca2<tm1Brn>,Trp53<tm1Brn>/Trp53<+>,Tg(KRT14-cre)8Brn/0
  http://metadb.riken.jp/0010300I129P2OlaHsdFVBNBrca2tm1BrnBrca2tm1BrnTrp53tm1BrnTrp53TgKRT14cre8Brn0Trp53tm1BrnTrp53TgKRT14cre8BrnBrca2tm1Brn
• increased mammary adenocarcinoma incidence_Brca2<tm1Brn>/Brca2<tm1Brn>,Trp53<tm1Brn>/Trp53<+>,Tg(KRT14-cre)8Brn/0
  http://metadb.riken.jp/0001883I129P2OlaHsdFVBNBrca2tm1BrnBrca2tm1BrnTrp53tm1BrnTrp53TgKRT14cre8Brn0Trp53tm1BrnTrp53TgKRT14cre8BrnBrca2tm1Brn
• no abnormal phenotype detected_Brca2<tm1Brn>/Brca2<tm1Brn>
  http://metadb.riken.jp/0002169I129P2OlaHsdFVBNBrca2tm1BrnBrca2tm1BrnBrca2tm1Brn
• embryonic lethality, complete penetrance_Brca2<tm1.1Brn>/Brca2<tm1.1Brn>
  http://metadb.riken.jp/0011092I129P2OlaHsdBALBcJFVBNBrca2tm11BrnBrca2tm11BrnBrca2tm11Brn
• abnormal embryo development_Brca2<tm1.1Brn>/Brca2<tm1.1Brn>
  http://metadb.riken.jp/0001672I129P2OlaHsdBALBcJFVBNBrca2tm11BrnBrca2tm11BrnBrca2tm11Brn
• embryonic growth retardation_Brca2<tm1.1Brn>/Brca2<tm1.1Brn>
  http://metadb.riken.jp/0003984I129P2OlaHsdBALBcJFVBNBrca2tm11BrnBrca2tm11BrnBrca2tm11Brn